Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 1;6(6):881-887.
doi: 10.1001/jamaoncol.2020.0809.

Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma

Michael J Raphael  1   2 , Gary Ko  2 , Christopher M Booth  2   3   4 , Susan B Brogly  4   5 , Wenbin Li  4 , Maria Kalyvas  2   6 , Timothy P Hanna  2   4   6 , Sunil V Patel  2   4   5
Affiliations

Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma

Michael J Raphael et al. JAMA Oncol. .

Abstract

Importance: Definitive chemoradiation for anal cancer is effective but may be associated with toxic effects, and some patients may not be able to complete the planned treatment. Identifying factors associated with treatment interruption and noncompletion is important to target quality improvement efforts.

Objective: To identify rates of chemoradiation treatment interruption or noncompletion and factors associated with this among patients with anal cancer treated in routine clinical practice.

Design, setting, and participants: In this population-based, retrospective cohort study, the Ontario Cancer Registry was used to identify all incident cases of squamous cell anal cancer treated with curative-intent radiation from 2007 to 2015 in Ontario, Canada. Final analysis of data was performed on August 9, 2019.

Exposures: Curative-intent radiation therapy.

Main outcomes and measures: Treatment interruption was defined as more than 7 days between fractions of radiation. Radiation completion was defined as receipt of 45 Gy or more and 25 fractions of radiation. Chemoradiation completion was defined as radiation completion and 2 doses of combination chemotherapy. Associations between patient factors and treatment interruption and noncompletion were estimated with log-binomial models. Cox proportional hazard models were used to estimate the association of treatment interruption or noncompletion with all-cause death, cancer-specific death, and the combined outcome of colostomy or death.

Results: Overall, 1125 patients with stage I-III anal cancer were treated with curative-intent radiation. Treatment interruptions occurred in 262 (23%). Radiation and chemoradiation noncompletion occurred in 199 (18%) and 280 (25%), respectively. No associations were found to correlate with an increased risk of treatment interruption. Patients older than 70 years were less likely to complete chemoradiation (risk ratio [RR], 0.60; 95% CI, 0.52-0.70), compared with those younger than 50 years. Patients with a higher number of comorbidities were also less likely to complete chemoradiation (RR, 0.70; 95% CI, 0.51-0.95). Patients who did not complete chemoradiation had a higher risk of requiring salvage abdominoperineal resection (RR, 1.54; 95% CI, 1.03, 2.31), overall death (hazard ratio [HR], 1.54; 95% CI, 1.23-1.92), cancer-specific death (HR, 1.59; 95% CI, 1.14-2.22), and colostomy or death (HR, 1.80; 95% CI: 1.10-2.93). Treatment interruptions longer than 7 days were not associated with death.

Conclusions and relevance: Many patients undergoing curative-intent chemoradiation for anal cancer experienced treatment interruption or noncompletion. Quality improvement initiatives to optimize treatment continuity and completion are needed.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Population CONSORT Diagram
OCR Indicates Ontario Cancer Registry; SCCA, squamous cell carcinoma of the anal canal.
Figure 2.
Figure 2.. Overall Survival and Treatment Completion and Interruption Status
A. Association between radiation treatment completion status and survival. B, Association between chemoradiation treatment completion status and survival. C, Association between radiation treatment interruption status and survival.
See this image and copyright information in PMC

Comment in

References

    1. Surveillance, Epidemiology, and End Results (SEER) : Anal Cancer, 2018. https://seer.cancer.gov/statfacts/html/anus.html. Accessed March 23, 2020.
    1. Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. 2013;31(12):1569-1575. doi:10.1200/JCO.2012.45.2524 - DOI - PMC - PubMed
    1. Benson AB III, Venook AP, Al-Hawary MM, et al. . Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(7):852-871. doi:10.6004/jnccn.2018.0060 - DOI - PMC - PubMed
    1. Glynne-Jones R, Nilsson PJ, Aschele C, et al. ; European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO) . Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40(10):1165-1176. doi:10.1016/j.ejso.2014.07.030 - DOI - PubMed
    1. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348(9034):1049-1054. doi:10.1016/S0140-6736(96)03409-5 - DOI - PubMed

Substances

Supplementary concepts